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Background: Longitudinal neuroimaging studies of major depressive disorder (MDD) have most commonly
assessed the effects of antidepressants from the serotonin reuptake inhibitor class and usually reporting a single
measure. Multimodal neuroimaging assessments were acquired from MDD patients during an acute depressive
episode with serial measures during a 12-week treatment with the serotonin-norepinephrine reuptake inhibitor
(SNRI) duloxetine.
Methods: Participants were medication-free MDD patients (n = 32; mean age 40.2 years) in an acute depressive
episode and healthy controls matched for age, gender, and IQ (n = 25; mean age 38.8 years). MDD patients received
treatment with duloxetine 60 mg daily for 12 weeks with an optional dose increase to 120 mg daily after 8 weeks.
All participants had serial imaging at weeks 0, 1, 8, and 12 on a 3 Tesla magnetic resonance imaging (MRI) scanner.
Neuroimaging tasks included emotional facial processing, negative attentional bias (emotional Stroop), resting state
functional MRI and structural MRI.
Results: A significant group by time interaction was identified in the anterior default mode network in which
MDD patients showed increased connectivity with treatment, while there were no significant changes in healthy
participants. In the emotional Stroop task, increased posterior cingulate activation in MDD patients normalized
following treatment. No significant group by time effects were observed for happy or sad facial processing,
including in amygdala responsiveness, or in regional cerebral volumes. Reduced baseline resting state connectivity
within the orbitofrontal component of the default mode network was predictive of clinical response. An early
increase in hippocampal volume was predictive of clinical response.
Conclusions: Baseline resting state functional connectivity was predictive of subsequent clinical response.
Complementary effects of treatment were observed from the functional neuroimaging correlates of affective
facial expressions, negative attentional bias, and resting state. No significant effects were observed in affective
facial processing, while the interaction effect in negative attentional bias and individual group effects in resting
state connectivity could be related to the SNRI class of antidepressant medication. The specificity of the observed
effects to SNRI pharmacological treatments requires further investigation.
Trial registration: Registered at clinicaltrials.gov (NCT01051466).
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Major depressive disorder (MDD) is characterized by
a prolonged low mood, neurovegetative disturbances,
and cognitive impairments. Neuroimaging has aided
in the delineation of the neural circuitry of MDD
[1,2], determination of the effects associated with a
course of therapy [3-5], provision of novel insights for
neuropsychological models [2], and the potential for
the development of prognostic and diagnostic bio-
markers [6,7].
Within the neural circuitry of MDD, the intensity of
engagement and their regional distribution depend in
part on the emotional and cognitive features of the
particular task. For example, in response to negative
stimuli, MDD patients tend to show greater responsivity
in the amygdala, dorsal anterior cingulate and insula, but
reduced activity in the dorsolateral prefrontal cortex and
striatum relative to healthy participants, while measures of
resting state have most commonly revealed greater re-
gional cerebral blood flow in the thalamus [5]. Studies
have generally reported findings from a single task, while
concurrently acquired, multiple functional and structural
measures may provide a more comprehensive assessment
[1-6,8]. Furthermore, longitudinal treatment studies
have most frequently investigated the serotonin reuptake
inhibitors (SRI), in which reduced activity in subcortical
and limbic regions in MDD patients has been noted
following treatment [3-5]. However, the effects of the
SRI class of antidepressants may not necessarily be
extrapolated to norepinephrine reuptake inhibitors
(NRI) [9-12].
The present study is a multimodal investigation of the
functional and structural neuroanatomy of depression
in a prospective, longitudinal design with the dual
serotonin-norepinephrine reuptake inhibitor (SNRI)
duloxetine. MDD patients participated in MRI scans
during an acute depressive episode and during the course
of treatment, and healthy controls had the same scans at
the same time points. Our main hypothesis was that
treatment would be associated with normalization of
anterior cingulate and amygdala activation in response
to sad faces in MDD patients as compared with healthy
participants [3-5].
Methods
The study was approved by the Cambridgeshire 4 Research
Ethics Committee, NHS Research Ethics Committee,
National Research Ethics Service, NHS Health Research
Authority, and all participants provided informed written
consent. The study was conducted in conformity with the
Declaration of Helsinki and its amendments. Study proce-
dures and implementation were consistent with Good
Clinical Practice Guidelines and all applicable regulatory
requirements.Participants
Participants were recruited from the general community
by newspaper advertisement. Inclusion criteria for all
participants were an age range of 25 to 65 years and
being right-handed. MDD patients met criteria for a single
episode of MDD or recurrent MDD, without psychotic
features, as defined by the Diagnostic Statistical Manual
of Mental Disorders, Fourth edition, text revision
(DSM-IV-TR) [13] and assessed with the Structured
Clinical Interview for DSM-IV Axis I disorders (SCID-IV)
[14]; were free of current antidepressant medication for a
minimum of 6 weeks for fluoxetine treatment or 4 weeks
for other antidepressant medication before the start of
treatment at baseline (week 0); and had a 17-item
Hamilton Rating Scale for Depression (HRSD-17) [15,16]
total score ≥ 18 at the screening assessment and baseline.
Healthy participants were matched by age, gender,
and intelligence quotient (IQ); had HRSD-17 total
score ≤ 7 at screening and baseline; and did not meet
criteria for MDD based on SCID-IV. IQ was evaluated with
the Wechsler Adult Intelligence Scale-III UK (WAIS-III
UK) [17].
Exclusion criteria were any significant comorbid medical
or psychiatric disorders, as defined by DSM-IV-TR Axis I
or II disorder including a history of substance abuse
or dependence within the prior 6 months, excluding
nicotine and caffeine; known Alzheimer’s disease or
mental retardation; serious suicidal risk or risk of
self-harm (Columbia-Suicide Severity Rating Scale)
[18]; history of electroconvulsive therapy, transcranial
magnetic stimulation, or vagus nerve stimulation within
the past year; abnormal thyroid stimulating hormone
concentration; or medical disorders known to affect
central nervous system structures or function.
Enrolled in the study were 32 MDD patients, having
a moderate to severe severity of depression (mean
HRSD-17 = 22.4 (standard deviation (SD) = 2.7)), and 28
healthy participants, with no significant between-group
differences in demographics (Table 1). Twenty-four MDD
patients and 23 healthy participants completed all the
serial MRI scans.
Study design
The protocol consisted of a 12-week treatment period
for MDD patients with duloxetine at a dosage of 60 mg
once daily for the first 8 weeks. At week 8, MDD
patients whose symptoms met criteria for remission
continued taking 60 mg once daily, while those who
did not had an optional dosage-increase up to 120 mg
once daily (Additional file 1: Figure S1).
At baseline, MDD severity was evaluated with the
following scales: SCID-IV [13], HRSD-17 [14,15], Hamilton
Anxiety Rating Scale (HAMA) [19], Columbia-Suicide
Severity Rating Scale (C-SSRS) [18], Clinical Global
Table 1 Demographics and baseline characteristics
MDD patients Healthy participants
Number 32 25a
Age 40.2 (11.2) 38.8 (9.9)
Age range 25.0-57.9 27.3-58.2
Male 19 (59.4 %) 12 (48.0 %)
Ethnicity
White 18 (56.3 %) 15 (60.0 %)
Asian 10 (31.3 %) 3 (12.0 %)
African descent 4 (12.5 %) 7 (28.0 %)
Current alcohol use 22 (68.8 %) 19 (76.0 %)
Current tobacco use 6 (18.8 %) 1 (4.0 %)
HRSD-17 22.4 (2.7) 0.5 (1.3)
HAMA 21.1 (5.8) 0.4 (0.9)
WAIS-III 107.4 (11.2) 109.2 (14.6)
CGI-S 4.4 (0.6) 1.0 (0.0)
PGI-S 3.8 (1.1) NA
SDS 19.3 (5.4) 0.2 (0.8)
All values are presented as mean and standard deviation in parenthesis,
except where indicated. Age is in years. Number of participants and
percentage of participants are presented for Male gender, Ethnicity, Current
alcohol and tobacco use. Total scores are presented for HRSD-17, HAMA,
WAIS-III and SDS. Participants were matched by age (p = 0.62), gender (p = 0.39),
and WAIS-III IQ (p = 0.61) with no significant difference between groups, similarly
for alcohol (p = 0.55) and drug use (p = 0.12). Abbreviations: CGI-S, Clinician Global
Impression of Severity scale; HAMA, Hamilton Anxiety Rating Scale; HRSD-17,
17-item Hamilton Rating Scale for Depression; MDD, major depressive disorder;
NA, not applicable; PGI-S, Patient Global Impression of Severity scale; SDS,
Sheehan Disability Scale; WAIS-III, Wechsler Adult Intelligence Scale third UK edition.
aexcluding 3 inadvertently enrolled healthy participants who did not meet
entry criteria.
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Impression of Severity scale (PGI-S) [20], and Sheehan
Disability Scale (SDS) [21]. IQ was evaluated with the
WAIS-III UK [17] at weeks 0, 1, or 4. At each subsequent
visit, the following assessments were performed: clinical
assessment and administration of HRSD-17, HAMA,
CGI-S, SDS, and PGI-S by a consultant psychiatrist or
senior resident in psychiatry under supervision by a
consultant psychiatrist. Response to treatment was defined
as a minimum of 50% reduction from the week 0 (baseline)
HRSD-17 total score. Remission was defined as an
endpoint HRSD-17 total score of ≤ 7. During the study,
safety and tolerability to treatment was assessed
through collection and monitoring of discontinuation
rates, treatment-emergent adverse events, serious adverse
events, vital signs, laboratory analyses, and clinical assess-
ments including questioning of suicide-related behavior
and ideations using the C-SSRS.
Healthy participants were evaluated at baseline with
the following rating scales: SCID-IV, HAMA, and
WAIS-III UK. All visits were reviewed with a consultant
psychiatrist.Functional and structural MRI data acquisition
Magnetic resonance imaging (MRI) scans were acquired
on a 3 Tesla GE SIGNA HDx (Milwaukee, WI, USA) at
King’s College London. MRI scans were acquired at
weeks 0, 1, 8, and 12 for all participants.
Structural MRI scan
A high-resolution 3-dimensional sagittal T1-weighted struc-
tural image was acquired at each session (Magnetization
Prepared Rapid Gradient Echo; resolution 1 mm3). The
functional MRI tasks included affective facial expressions
[4,22,23], negative attentional bias task (emotional Stroop)
[24], and resting state [8].
Affective facial expressions functional MRI task
The event-related functional MRI paradigm consisted of
facial expressions and baseline trials presented in a
random order [4,22,23]. Each facial stimulus was pre-
sented twice at each intensity (60 faces in total), along
with 12 baseline trials consisting of a crosshair for a total
of 72 presentations. Facial stimuli consisted of 10 faces
(5 females) adapted from Pictures of Facial Affect by
Ekman and Friesen morphed to represent varying inten-
sities: low, medium and high [25]. Each stimulus was
presented for 3 seconds. The interval between trials
varied randomly according to a Poisson distribution,
with a mean intertrial interval of 5 seconds, for a total
duration of 360 seconds (6 minutes). Participants were
instructed to specify the gender of the face (male, female),
and responses were made by pressing a button.
Gradient echo T2*-weighted echoplanar images were
acquired depicting blood oxygenation level-dependent
(BOLD) contrast. A total of 180 volumes were acquired
for each for the happy and sad facial tasks. For each vol-
ume, 39 oblique axial slices parallel to the intercommissural
plane were collected with the following parameters:
slice thickness: 3 mm, slice gap: 0 3 mm, echo time (TE):
30 milliseconds, repetition time (TR): 2000 milliseconds,
flip angle: 75°, field of view: 240 mm, and matrix size:
64 × 64.
Emotional Stroop functional MRI task
The emotional Stroop task consisted of 40 negative and
40 neutral words presented in alternating blocks of eight
words per emotional and neutral category, repeated
five times. Each word was presented only once with a
presentation time of 700 milliseconds per word. All
words appeared on a dark grey background in red,
blue, green, or yellow color, pseudo-randomized across
the two valence categories. Four different stimulus sets
which varied in the order of presentation of emotional
and neutral word category blocks were randomized
between scan sessions. The task was projected onto a
screen and viewed from a mirror inside the scanner.
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as quickly as possible. A microphone was used to rec-
ord vocal responses and to provide auditory feedback
of vocal input. Reaction times to the onset of the
vocal responses were measured. Verbal responses during
the MRI scan were made in the absence of scanner
noise as a clustered fMRI image acquisition sequence
was used [24].
The emotional Stroop task was acquired in 133
T2*-weighted echoplanar images, for each volume: 39
oblique axial slices parallel to the intercommissural
plane collected over 2000 milliseconds, allowing for a
silent period of 2000 milliseconds in a clustered fMRI
acquisition. TE: 30 milliseconds, flip angle: 90°, slice
thickness: 3 mm, interslice gap: 0.3 mm, matrix size:
64 × 64. The first 4 volumes collected were acquisitions to
allow for T1 equilibrium effects.
Resting state functional MRI
Whole-brain functional resting state data were collected
while participants were instructed to stay awake with
their eyes closed and not to think of anything specific.
Scan duration was 8.5 minutes. T2*-weighted single-shot
gradient echo echoplanar sequence was acquired with
the following parameters: TE: 30 milliseconds, TR:
2 seconds, FA: 75°, voxel size, 3.75 × 3.75 × 3.3 mm.
Headphones and cushions were used to minimize
scanner noise and head motion, respectively.
Pre-specified primary outcome measure and secondary
analyses
The pre-specified primary outcome measure was the
mean percentage signal change in functional MRI BOLD
contrast response from baseline to week 12 in the mean
of the right and left amygdalae, in response to sad facial
affect processing, comparing MDD and healthy partici-
pants. The sample size for the study was based on effect
size estimates for this primary outcome, obtained from
our previous work on pre- to post- SRI treatment effects
on amygdala activation in MDD patients relative to
healthy controls [4].
Secondary outcomes included baseline-to-endpoint
changes in illness severity, as assessed by HRSD-17,
HAMA, CGI-S, Patient Global Impression of Improvement
scale, and SDS global functioning impairment score, and
their correlation with changes in structural and functional
correlates over sessions in the following regions of interest:
anterior cingulate cortices, amygdalae, and hippocampi.
Changes in functional MRI BOLD contrast response and
volumes of each region of interest from week 0 to weeks 1,
8, and 12 were analyzed using a restricted maximum
likelihood-based mixed-effects model repeated measures
(MMRM) approach. The model included the categorical
effects of group, visit, and group-by-visit interaction as wellas the continuous covariate of baseline measurement. Sig-
nificance tests were based on least-square mean changes
and Type III sum-of-square, implemented using SAS
PROC MIXED (SAS, version 9 1, Cary, NC, USA). Logistic
regression was also used to examine the association
between endpoint remission and changes in neural
correlates. The region-of-interest analyses were per-
formed in all enrolled participants, using MMRM
model or last observation carried forward (LOCF)
methodology for missing observations (eg. participants
who did not complete the study). No multiple compari-
sons correction procedures were applied to the MMRM
analyses as these were pre-specified.
As well, functional whole-brain image analyses were
conducted on a complete case basis involving each scan
session (ie. with participants who participated in all
four MRI scans) as standard software for whole-brain
neuroimaging analysis does not permit “missingness”
in the data set of images. As explained in detail
below, whole-brain image analyses were focused on
functional changes over time in the treatment and
control samples, as well as prediction of treatment
improvement (with HRSD-17 or HAMA) from baseline
functional measurements. Complete data available for
each task were varied due to scan acquisition difficulties,
such as excessive movement during the scan and late
arrival of participants leading to incomplete scan
sessions. The number of participants who completed
these tasks for all the scan sessions: happy and sad
faces (23 MDD and 23 healthy participants); emotional
Stroop (21 MDD and 20 healthy participants); and resting
state (21 MDD and 20 healthy participants). Behavioral
data are presented in the Additional file 1.
Functional and structural MRI analysis
Structural MRI analysis
Analysis of the structural images was performed with
Freesurfer 4.5.0 automated longitudinal stream to
obtain the volumes of a priori regions of interest:
anterior cingulate cortices, amygdalae, and hippocampi
[26]. Quality control was performed by visually assessing
each Freesurfer brain segmentation overlaid on the
original T1 image to ensure that cortical reconstructions
did not present major anomalies. The medial temporal
lobe region was assessed with coronal sections. All recon-
structions passed this qualitative control, and the original
Freesurfer outputs were used without manual correc-
tions. High intraclass correlations (ICC) for repeated
measurements were observed for all the volumetric mea-
surements in the healthy control participants (all > 0.91)
(Additional file 1: Table S1). Volumetric measurements of
the amygdalae, hippocampi and anterior cingulate were
included in second-level MMRM and logistic regression
models.
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Statistical Parametric Mapping (SPM8, Wellcome
Department of Imaging Neuroscience, London, UK)
was used to preprocess and analyze the task-related
fMRI data. Images were realigned to correct for motion
artifacts, spatially normalized to the Montreal Neurological
Institute template, and smoothed using an 8-mm
full-width at half maximum Gaussian kernel filter.
Group analysis used a random effects model consisting of
a 2-stage hierarchical procedure with the first-level
analysis performed by using the general linear model,
accounting for serial autocorrelations by application
of an autoregressive model.
Affective facial expressions task
In the sad and happy faces tasks, stimuli presentations
were modeled as individual events, and the first-level
analysis produced contrast images relevant to the main
contrast of interest (sad faces or happy faces vs. crosshair
baseline). For the primary outcome measure, the MarsBar
SPM toolbox was used to estimate mean activation in the
a priori regions of interest.
Emotional Stroop task
In the emotional Stroop task, the first-level analysis pro-
duced individual mean images corresponding to the
main contrast of interest (negative > neutral) and the
time series was modeled as a block-design.
Second-level analysis of task-related functional tasks
For each task, its second-level analysis employed a
random-effects model to examine the main effect of
group (MDD vs. healthy participants across all time
points), main effect of time (linear changes over weeks 0,
1, 8, and 12) and the group by time interaction. T-tests
were also used to compare scanning data at a particular
time point between groups. Inference of whole-brain
statistical images was conducted using the general linear
model and cluster-wise family-wise error rate control with
p< 0.05 corrected for multiple comparisons. For post hoc
analyses only, in order to identify the direction of changes
responsible for an interaction effect, less conservative
thresholds were also employed as indicated in the
Results section.
Functional MRI analysis: resting-state data
Resting-state analysis was performed using FMRIB Software
Library (FSL) v5.0 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/).
Preprocessing included motion correction, skull stripping,
spatial smoothing at 5 mm full-width at half maximum,
and registration to standard space. Extraction of resting-
state networks at the group level was conducted by
using FSL Multivariate Exploratory Linear Optimized
Decomposition into Independent Components (MELODIC)[27]. MELODIC was set to estimate 25 components
to extract stable connectivity estimates of the default
mode networks (DMNs) [8]. Five independent components
depicting DMN activity were identified (Additional file 1:
Figure S2) [28], encompassing the canonical default mode
inclusive of the two core regions (anterior medial prefrontal
and posterior cingulate cortices), dorsomedial prefrontal
subsystem (dorsomedial prefrontal cortex, lateral temporal
cortex, and temporoparietal junction), and medial temporal
lobe subsystem (ventromedial prefrontal cortex including
ventral cingulate, parietal lobule, retrosplenial cortex, and
hippocampal formation) [29,30]. Dual regression was used
to generate participant-specific and scan session–specific
versions of group-level DMN spatial maps in two stages,
resulting in a set of participant-specific spatial maps for
each scan session and participant. Second-level analysis of
resting-state data: Scan-specific maps were used to estimate
contrast maps depicting linear changes across succes-
sive scans for each participant. These statistical maps
(one per participant) were entered in a higher-level
general linear model analysis, and statistical inference
was performed with nonparametric permutation testing
[31]. Correction for multiple comparisons was conducted
using threshold-free cluster enhancement with family-
wise error (FWE) rate control with p < 0.05 corrected for
multiple comparisons [32].Results
Clinical measures
MDD patients showed a significant improvement in
their depression, as assessed by changes in HRSD-17
(−13.9 [7.0]); HAMA (−11.5 [8.6]); SDS global functioning
impairment score (−9.8 [8.9]); and CGI-S (−2.2 [1.3]).
Upon study completion at week 12, 18 MDD patients
(75.0% of MDD completers) fulfilled criteria for remission
and 19 MDD patients (79.1%) fulfilled criteria for clinical
response. Applying the last observation carried forward
analysis with inclusion of all enrolled participants, there
were no significant differences in the history of depression
between responders (n = 20, median 1 episode, mean
2.7 [4.43]) and non-responders which included MDD
participants who did not complete the study (n = 7,
median 2 episodes, mean 6.14 [10.53]) (p = 0.43). The
frequency and nature of adverse events were consistent
with the known profile of duloxetine [33], and there
was one serious adverse event of retinal pigment
epitheliopathy which was not judged to be related to
the study or duloxetine.Structural magnetic resonance imaging
There were no significant group by time effects nor any
baseline differences in anterior cingulate cortices, amygda-
lae, or hippocampi volumes (Additional file 1: Table S1).
Figure 1 Emotional Stroop. A significant group by time effect was
found for the emotional Stroop in the posterior cingulate extending
into the precuneus.
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Contrary to our hypothesis, there were no significant
between group differences in the change in BOLD response
from baseline to sad faces as analyzed with the MMRM
approach nor any significant group by time effects from the
whole-brain analysis. There were no significant differences
between groups at baseline (Additional file 1: Table S1).
Within the MDD group, a main effect of time was
observed in which there was a significant increase in
the BOLD response to the mean of the medium and
high intensity of expressions in the posterior cingulate/
precuneus (x = −3, y = −43, z = 19; 221 voxels; peak
T = 4.50; p (FWE corrected) = 0.010), while healthy
participants showed a trend towards a decrease in the
orbitofrontal region (x = 45,y = 29, z = 11; 118 voxels,
T = 4.61, p (FWE corrected) = 0.068).
Similarly, no significant group by time effects or any
baseline differences between groups were observed in
the happy faces task. There were no main effects of time
in the MDD patients, but healthy participants showed a
significant decrease with time in response to the mean
of medium and high intensity of expressions in the
anterior cingulate (x = 9, y = 29, z = 40; 315 voxels,
peak T = 4.27; p (FWE corrected) = 0.002) and precentral
region (x = −51, y = 11, z = 34; 190 voxels; T = 4.08; p (FWE
corrected) = 0.018), as well as approaching significance in
the thalamus (x = 3, y = −13, z = 10; 118 voxels; T = 4.12;
p (FWE corrected) = 0.070).
Emotional Stroop
A significant group by time interaction was observed in
the left posterior temporoparietal junction involving the
parahippocampal cortex (x = −18, y = −40, z = 1; 414 -
voxels; peak T = 4.11; p (FWE corrected) = 0.014) as well
as precuneus and posterior cingulate cortex (subordinate
peaks at x = −24, y = −52, z = 22 and x = −21, y = −70,
z = −10) during the processing of negative relative to
neutral words (Figure 1). The interaction effect was
found to be driven by reductions observed in MDD
patients (significant at p = 0.001 uncorrected) with
successive scans relative to healthy participants who
showed no significant changes with time. At baseline,
there was a main effect of group in which MDD patients
showed greater activation relative to healthy participants
in a region including the posterior cingulate cortex and
precuneus bilaterally (right: x = 9, y = −43, z = 19; left:
x =−15,y =−43, z = 4, and x = 15, y =−49, z = 13; -134 voxels;
peak T = 4.51; p (FWE corrected) = 0.026).
Resting state
No significant group by time effects were found, but
main effects of time were observed within each group.
MDD patients showed decreased connectivity with suc-
cessive scans (Figure 2) between DMN components andbilateral prefrontal cortices, namely with right dorsolateral
(IC06; x = 52, y = 10, z = 18; 118 voxels; T = 3.9; 117 voxels;
p (FWE corrected) = 0.034), right superior frontal premotor
cortex (IC06; x = 22, y = −2, z = 64; T = 4.25; 41 voxels;
p (FWE corrected) = 0.030), and left inferior frontal
gyrus (IC06; x = −54, y = 14, z = 16; T = 4.79; 36 voxels;
p (FWE corrected) = 0.018), as well as decreased con-
nectivity between DMN components and auditory
processing cortex (IC10; x = −57, y = −48, z = 19; T = 5.85;
1078 voxels; p (FWE corrected) = 0.007), and primary
visual and extrastriate regions (IC20; x = 2, y = −78, z = 4;
T = 4.88; 492 voxels; p (FWE corrected) = 0.005). Increases
in connectivity between components of the DMN in
MDD patients were found with medial prefrontal regions,
including pregenual and subgenual cingulate and the
frontal pole (IC08; x = 10, y = 30, z = −8; T = 5.04;
7287 voxels; p (FWE corrected) = 0.007), right hippocam-
pus (IC24; x = 42, y = 14, z = −36; T = 4.13; 30 voxels; p
(FWE corrected) = 0.023), parahippocampal gyrus (IC24;
x = 42, y = −30, z = −20; T = 4.05; 431 voxels; p (FWE
corrected) = 0.035), angular gyrus (IC08; x = 54, y = −46,
z = 24; T = 4.99; 190 voxels; p (FWE corrected) = 0.010),
and middle occipital gyrus (IC08; x = 10, y = −102, z = 8;
T = 5.69; 263 voxels; p (FWE corrected) = 0.009). Healthy
participants showed decreased connectivity with time
between the DMN with the posterior hippocampus
extending into the fusiform region (IC06; x = 30, y = −38,
z = 0; T = 4.83; 45 voxels; p (FWE corrected) = 0.027).
There was also increased connectivity with time in healthy
participants between the DMN and posterior cingulate
(IC08; x = 6, y = −50, z = 8; T = 3 78; 85 voxels; p (FWE
corrected) = 0.030), fusiform gyrus (IC08; x = 34; y = −38,
z = −12; T = 4.61; 375 voxels; p (FWE corrected) = 0.010),
superior medial frontal gyrus (IC08; x = 2; y = 34, z = 36;
Figure 2 Resting-state functional magnetic resonance imaging. Linear changes in resting-state functional fMRI with successive scans, Areas with
reductions in connectivity to the default mode network (DMN) regions with time are shown in blue, and areas with increased connectivity to the
DMNs are depicted in red.
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cortex (IC08; x = −26; y = 10, z = 52; T = 4.19; 91 voxels;
p (FWE corrected) = 0.025), and parietal lobule (IC08;
x = 50; y = −54, z = 44; T = 4.30; 808 voxels; p (FWE
corrected) = 0.006).
Predictors of clinical response
Baseline resting-state activity within the orbitofrontal
component of the DMN in MDD patients, before
treatment was initiated, was negatively correlated with
improvement with treatment as measured by HRSD
(Figures 3 and 4). MDD patients with reduced
connectivity in the orbitofrontal component of the
DMN (BA10/25/47) (left subgenual anterior cingulate
(BA 25/11): x = 6, y = 30, z = −10; T = 6.84, 691 voxels;
p (FWE corrected)- = 0.003; right subgenual/pregenual
anterior cingulate: x = 12, y = 42, z = 8; T = 5.56;
83 voxels; p (FWE corrected)- = 0.021) showed the
greatest improvement with treatment. No other functional
MRI or structural baseline measures were correlated withFigure 3 Baseline connectivity in ventral cingulate and orbitofrontal resting
and orbitofrontal resting-state network predicted an improved response in
to week 12 corrected for multiple comparisons.changes in HRSD or HAMA based on the whole-brain
analysis.
From the MMRM model, which accounted for par-
ticipants who had not completed all the scans with a
last observation carried forward methodology, an early
increase in left hippocampal volume after 1 week of
treatment predicted clinical remission following
12 weeks of treatment (odds ratio 1.01 (95% CI: 1.00, 1.02)
p = 0.031) (Additional file 1: Table S2- S3). High intraclass
correlations for repeated measurements were observed
for all the volumetric measurements in the healthy
control participants (all > 0.91), which were 0.976 and
0.961 for the right and left hippocampi, respectively
(Additional file 1: Table S1).
Discussion
Distinct neural effects of treatment with duloxetine were
revealed in resting state connectivity, affective facial
processing, and negative attentional processing. Contrary
to our hypothesis, we did not find any group by timestate network. Decreased baseline connectivity in ventral cingulate
correlation with the normalized change in HRSD-17 score from week 0
Figure 4 Association between baseline connectivity and change in depressive severity. Scatter plot of baseline resting-state fMRI baseline
connectivity activity in subgenual cingulate and clinical response to 12 weeks of treatment with duloxetine as measured by the normalized
change in HRSD-17 score from week 0 to week 12.
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expressions [3-5]. Instead, marked effects in the posterior
cingulate cortex were evident in response to a task
designed to engage the negative attentional bias in MDD
[24], and there were time-dependent changes in the DMN
in MDD patients in which increased connectivity towards
limbic regions but decreased connectivity with lateral
cortical regions emerged as treatment progressed.
Furthermore, baseline resting state connectivity within
the orbitofrontal component of the DMN, namely in the
bilateral anterior cingulate regions, was a significant a
predictor of clinical response.
Normalization of limbic hyper-responsiveness has
been commonly reported in MDD [3-5] and appears to
be specific to sad facial expressions [34]. However, we
did not observe increased amygdala activation to sad
faces in the acutely depressed MDD participants nor any
significant group by time effects following treatment.
Potential confounds include factors related to the sample
and task. In the present group, the depressive symptoms
was of a moderate to severe severity which is comparable
to previous samples in which increased amygdala responses
have been observed [3-5,34]. The present task used implicit
affective processing in order to increase the potential to
engage amygdala responsivity, while a masked presentation
may have more fully captured amygdalar automatic
processing [35,36], and the number of subjects and thedesign of the task, which was an event-related design
rather than a blocked design, may have limited the power
to observe a significant effect [35]. Furthermore, most
studies to date have examined the effects of the SRI class
of antidepressants [3-5,34]. Single doses of SRI medica-
tions in healthy participants have been associated with
decreased amygdala responses to emotional faces, while
single-dose NRIs lead to increased activation in medial
and frontal regions [11]. It is unclear whether the effects
of different classes of antidepressants are comparable as it
has been proposed that SRIs have an early attenuating
effects on emotional reactivity while NRIs have a more
modulatory effect on attention regulation of emotional
processes and may not necessarily have a direct impact
on amygdala responsivity which would be observed in
addition to potential state effects related to acute depres-
sive states as compared to states of remission [9-11,37].
In order to examine the negative attention bias in
MDD [38], we applied an emotional Stroop task [24,39].
We found a significant interaction effect in the posterior
cingulate cortex in which increased baseline activation
in MDD showed a linear normalization with successive
measures following treatment as compared to healthy
participants who underwent the same scans. The posterior
cingulate cortex is involved in the DMN, which has a cen-
tral role in many situations whereby attention is internally
directed such as in episodic memory retrieval and inner
Fu et al. BMC Psychiatry  (2015) 15:82 Page 9 of 11reflection [40]. Increased posterior cingulate activation in
MDD patients while acutely depressed may be understood
as reflecting a failure to attenuate self-referential activity,
perhaps leading to interference in task performance.
With treatment, attenuation of posterior cingulate activity
may reflect an improvement in selective attention and the
ability to focus.
In parallel, the resting-state functional connectivity in
MDD patients showed increased connectivity over the
course of treatment within the anterior DMN in the
subgenual anterior cingulate and regions involved in
attention-processing, namely the superior frontal and
parietal cortices, while reduced connectivity was observed
in the prefrontal regions linked to the DMN. Anand et al.
[41] also found increased connectivity with the anterior
cingulate and limbic regions following treatment with a
variety of antidepressant medications, and Li et al. [42]
have proposed that persistent increased functional con-
nectivity in anterior DMN reflects a trait effect of MDD
and a potential risk for relapse.
The present findings bring into question the potential
for amygdala responsivity as a state marker of MDD
because no significant differences were found during
an acute episode or following 12 weeks of treatment
in which the majority of patients’ symptoms fulfilled
criteria for clinical remission reflecting the numerous
factors which impact on amygdala responsivity [35].
Rather the negative affective bias appears to have been
more strongly detected by the emotional attention
processing task which revealed a significant group by
time effect with normalization of activation in the
posterior cingulate. The corresponding increase in
resting state connectivity in MDD patients with treatment
highlights potential links between the negative affective
bias that is characteristic of MDD and the resting state
network [37]. Moreover, there are persuasive indications
that these effects may be related to the NRI class of anti-
depressant medication [9-12,37] although this requires
further investigation.
As a potential marker of clinical response, we found
that MDD patients with reduced functional connectivity
with the subgenual anterior cingulate showed the greatest
clinical improvement following treatment. The subgenual
anterior cingulate has a key role in MDD [43], and activity
in this region has been consistently implicated as a
predictor of clinical response [7,44]. Increased functional
connectivity with the subgenual anterior cingulate has
been associated with increased length of illness [45], and
the neuropsychological mechanisms of rumination and
brooding have been correlated with increased connectivity
between the subgenual anterior cingulate and posterior
cingulate [46], including in treatment-naïve MDD patients
with increased functional connectivity in the medial
prefrontal and subgenual anterior cingulate [47]. Anteriorcingulate-limbic white matter tracts have also been pre-
dictive of clinical response [48], though the degree to
which white matter tract structural connectivity form the
basis of resting state functional connectivity requires
further validation [49].
From the MMRM model, an early increase in left
hippocampal volume after 1 week of treatment predicted
subsequent clinical response. Although the volume change
was small, the high intraclass correlations in hippocampal
volumes with the repeated measures in the healthy partici-
pants indicate a high reliability of the measure. Sämann
[50] reported that increased left hippocampal gray matter
volume was predictive of treatment response to a variety
of antidepressant medications, and our meta-analysis
supported the observation of reduced right hippocampal
volume being predictive of a poorer clinical response [7].
Increases in hippocampal volume have been observed
following short term [51] and long term [52] treatments
with antidepressant medications. Our finding suggests
that antidepressant medications can increase hippocampal
volume early in the course of treatment, such increases
may be predictive of clinical response, and provides
some corroboration for hippocampal neurogenesis as
a mechanism for the effects of antidepressant therapy [53].
Limitations
The high response rate in this open study though has
limited the power to detect differences between responders
and MDD patients with a more treatment-resistant form of
depression, which may be associated with distinct neural
correlates [41]. The absence of a placebo-control treatment
arm limits our attribution of effects to the antidepressant
medication as opposed to changes associated with clinical
improvement, although possible confounds of time were
accounted for by healthy participants having the same serial
scans. Furthermore, we did not find any significant
differences between MDD patients and healthy participants
in response to the happy and sad faces stimuli, perhaps in
part reflecting the poor test-retest reliability of amygdala
response to these emotional faces [54], while resting-state
fMRI data show greater robustness and reproducibility
[55]. Test-retest reliability of a neuroimaging measure
becomes particularly important in the development of
biomarkers for prognosis and diagnosis [44].
Conclusions
In summary, multimodal functional and structural neuro-
imaging correlates demonstrated significant effects of
treatment in the anterior DMN associated with resting
state connectivity and in response to negative attentional
biases, but not in response to happy or sad facial expres-
sions. Moreover, anterior cingulate functional connectivity
predicted clinical response. Our findings reflect the dis-
tinct effects of the SNRI class of antidepressants as well as
Fu et al. BMC Psychiatry  (2015) 15:82 Page 10 of 11methodological factors of test-retest reliability and repro-
ducibility of fMRI tasks. Further investigation is required
to examine the specificity of the SNRI effects.
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